Article
High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection.
Antiviral research - 1 Mar 2022
Liang Zhaochao, Shu Jingyi, He Qiyu, Zhang Fan, Dai Lizhong, Wang Ling, Lu Fengmin, Wang Lin
Abstract excerpt
Hepatitis E virus (HEV) is an important cause of viral hepatitis worldwide and there is currently no FDA-approved anti-HEV drug. The commonly used drug ribavirin (RBV) could not achieve viral clearance in all patients and can induce drug resistance. Recent studies showed sofosbuvir (SOF) can inhibit HEV replication in vitro and has add-on effect when combined with RBV, but the clinical effect of SOF against HEV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
